Cogent Biosciences (COGT) Income from Continuing Operations (2017 - 2020)
Historic Income from Continuing Operations for Cogent Biosciences (COGT) over the last 4 years, with Q4 2020 value amounting to -$11.4 million.
- Cogent Biosciences' Income from Continuing Operations fell 59478.49% to -$11.4 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$82.1 million, marking a year-over-year decrease of 15713.7%. This contributed to the annual value of -$82.1 million for FY2020, which is 15713.7% down from last year.
- Latest data reveals that Cogent Biosciences reported Income from Continuing Operations of -$11.4 million as of Q4 2020, which was down 59478.49% from -$57.2 million recorded in Q3 2020.
- In the past 5 years, Cogent Biosciences' Income from Continuing Operations ranged from a high of $2.3 million in Q4 2019 and a low of -$57.2 million during Q3 2020
- Moreover, its 4-year median value for Income from Continuing Operations was -$8.0 million (2018), whereas its average is -$10.9 million.
- As far as peak fluctuations go, Cogent Biosciences' Income from Continuing Operations soared by 12676.83% in 2019, and later crashed by 59478.49% in 2020.
- Quarter analysis of 4 years shows Cogent Biosciences' Income from Continuing Operations stood at -$6.8 million in 2017, then decreased by 26.77% to -$8.6 million in 2018, then skyrocketed by 126.77% to $2.3 million in 2019, then plummeted by 594.78% to -$11.4 million in 2020.
- Its last three reported values are -$11.4 million in Q4 2020, -$57.2 million for Q3 2020, and -$7.4 million during Q2 2020.